Evidence map›Paper›PMID 39339252›Full record

ArticlePharmaceutics2024

Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers.

Zhijun Miao, Xue Song, Anan Xu, Chang Yao, Peng Li, Yanan Li, Tao Yang, Gang Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhijun MiaoDepartment of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China.
Xue SongJiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Anan XuJiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Chang YaoDepartment of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China.
Peng LiDepartment of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China.
Yanan LiJiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Tao YangJiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.ORCID 0000-0003-2002-7326
Gang ShenDepartment of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China.

Funding

Gusu Innovation and Entrepreneurship Leading Talent Plan ZXL2022486National Natural Science Foundation of China 52373298Priority Academic Program Development of Jiangsu Higher Education Institutions PAPDProject of Suzhou Science and Technology Development Program SKJY2021029, SZM2023016Suzhou Industrial Park clinical medical expert team introduction projec 0202140004
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

human serum albuminimmunotherapySTING agonisttargeted delivery

Identifiers

PMID39339252
PMCPMC11434985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.